YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Madrigal Pharmaceuticals event puts genetics in focus Madrigal Pharmaceuticals (MDGL) drew fresh attention after publishing a secondary analysis of its Phase 3 MAESTRO-NASH trial, indicating that Rezdiffra's liver benefits appeared consist…
Madrigal Pharmaceuticals has delivered a very large 5 year gain for shareholders, and after that kind of rise the obvious question is whether the current share price still lines up with what the business is generating in sales today. The s…
Madrigal Pharmaceuticals recently reported in the Journal of Hepatology that a pre-specified secondary analysis of the Phase 3 MAESTRO-NASH trial found Rezdiffra (resmetirom) improved fibrosis, MASH resolution, liver fat and biomarker leve…
Novo NVO has an opportunity to extract greater value from semaglutide by expanding its use beyond traditional diabetes, obesity and cardiovascular indications. This strategy is increasingly relevant as the company faces intense competition…
Madrigal Pharmaceuticals, Inc. Secondary analysis of the Phase 3 MAESTRO-NASH trial demonstrated Rezdiffra improved histology and MRI-PDFF across common genetic variants associated with MASH progression CONSHOHOCKEN, Pa., Oct. 06, 2026 (GL…
Madrigal Pharmaceuticals, Inc. CONSHOHOCKEN, Pa., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated st…
[Interest rate percentage sign symbol finance investment graph chart] alexsl The Goldman Sachs equity team has rebalanced its Long Duration Basket amid rising interest rates. Equities usually struggle to digest sharp increases in interest…
The first commercial drug from Madrigal Pharmaceuticals (NASDAQ: MDGL) made a big splash in 2024 when the Food and Drug Administration (FDA) approved Madrigal's Rezdiffra as the first drug in the U.S. to treat metabolic dysfunction-associa…
[Health Care Medical Stock Market Industry Sector Wall Street Buildings 3d Illustration] iQoncept/iStock via Getty Images With the second-quarter earnings season now largely behind us, investors are turning their attention to how healthcar…
Madrigal Pharmaceuticals, Inc. CONSHOHOCKEN, Pa., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that the company will participate in the 2026 Cantor Global Healthcare Conference on Thursda…
Madrigal Pharmaceuticals, Inc. CONSHOHOCKEN, Pa., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated ste…
Altimmune ALT has entered a more capital-intensive stage with pemvidutide advancing across metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). Its larger cash posi…
Madrigal Pharmaceuticals, Inc. CONSHOHOCKEN, Pa., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated st…
Madrigal Pharmaceuticals, Inc. CONSHOHOCKEN, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated ste…
Madrigal Pharmaceuticals, Inc. CONSHOHOCKEN, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that the company will participate in the Canaccord Genuity 46th Annual Growth Conference on T…
Walmart downgraded, Palantir upgraded: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled…
Quick Read Easing Iran tensions, strong tech earnings, and a 5% oil price drop drove the Nasdaq up 2% and S&P 500 up 1.5% Monday. Deutsche Bank upgraded PLTR to Buy with a $200 target, while DZ Bank cut AAPL to Hold with a $310 target. Upc…
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Madrigal Pharmaceuticals (MDGL) drew attention after its second quarter 2026 earnings release, wh…
Madrigal Pharmaceuticals MDGL reported second-quarter 2026 loss of $1.99 per share, narrower than the Zacks Consensus Estimate of a loss of $2.55. In the same quarter last year, the company had incurred a loss of $1.50 per share. In the se…
Madrigal (MDGL) came out with a quarterly loss of $1.99 per share versus the Zacks Consensus Estimate of a loss of $2.55. This compares to a loss of $1.9 per share a year ago. These figures are adjusted for non-recurring items. This quarte…
Madrigal Pharmaceuticals, Inc. Second-quarter 2026 Rezdiffra® (resmetirom) net sales of $364.3 million, representing year-over-year growth of 71% As of June 30, 2026, more than 49,000 patients on Rezdiffra, more than doubling from 2Q25 ref…
Corcept Therapeutics (CORT) came out with quarterly earnings of $0.36 per share, beating the Zacks Consensus Estimate of a loss of $0.04 per share. This compares to earnings of $0.29 per share a year ago. These figures are adjusted for non…
Madrigal Pharmaceuticals, Inc. CONSHOHOCKEN, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated ste…
The weight-loss boom has created one of the market's biggest opportunities — and some of its most punishing failures. A single clinical result can send a stock soaring, wipe out years of gains, or threaten the company itself. Drug developm…
Madrigal Pharmaceuticals, Inc. CONSHOHOCKEN, Pa., July 16, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its second-quarter 2026 financial results on Thursday, July 30, 2026, pr…
Madrigal Pharmaceuticals, Inc. Received two new U.S. Rezdiffra® (resmetirom) patents in F2/F3; both patents will be listed in the FDA's Orange Book Received new U.S. resmetirom patent directed to a method of administering resmetirom to tre…
A relatively small group of companies capture much of Wall Street's attention and disproportionately affects the performance of major indexes like the S&P 500. It's not surprising, then, that many investors seeking attractive stocks natura…
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) is one of the 10 Best Under-the-Radar Stocks to Invest In. On June 11, BofA lowered its price target on Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) to $542 from $550. It maintained a Neutral ra…
Madrigal Pharmaceuticals, Inc. CONSHOHOCKEN, Pa., July 06, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated ste…
SUZHOU, China and MÖLNDAL, Sweden, July 2, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. (06938.HK), and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as "Ribo"), in collaboration with Madrigal Pharmaceutic…
Madrigal Pharmaceuticals, Inc. CONSHOHOCKEN, Pa., June 22, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated ste…
In late May 2026, Madrigal Pharmaceuticals reported new Phase 3 and real-world data at the EASL Congress showing Rezdiffra reduced multiple markers of cardiovascular and liver-related risk in MASH patients, including improvements in athero…
Altimmune ALT is heading into 2026 with a catalyst-heavy calendar tied to pemvidutide, its lead clinical asset. The setup is straightforward: investors are underwriting pivotal execution in metabolic dysfunction-associated steatohepatitis…
A month has gone by since the last earnings report for Madrigal (MDGL). Shares have lost about 7.9% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release, or is Mad…
CONSHOHOCKEN, Pa., June 04, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today ann…
Madrigal Pharmaceuticals, Inc. CONSHOHOCKEN, Pa., June 04, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated st…